Physician profile
Samuel Fox
NPI 1003381633
$14,601.83
in general payments reported to CMS, 2019-2025
30 companies · $2,722 in 2025
The $2,722 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,256 · 2022: $2,644 · 2023: $2,851 · 2024: $3,129 · 2025: $2,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,494 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,493.74 |
| Education | $208.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $3,164.38 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $1,518.85 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,191.35 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Janssen Biotech, INC. | $1,136.38 | 2021-2024 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $1,066.48 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $834.44 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $768.31 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $757.83 | 2021-2025 | Jublia, Siliq, Targretin |
| Galderma Laboratories, L.P. | $576.58 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Ucb, INC. | $504.42 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $471.68 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $455.62 | 2023-2025 | Zoryve |
| Pfizer INC. | $442.84 | 2021-2025 | |
| Amgen INC. | $415.01 | 2021-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $294.02 | 2022-2024 | Sotyktu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $287.40 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $172.30 | 2021-2025 | |
| Organon LLC | $80.87 | 2025 | Vtama |
| Genzyme Corporation | $77.33 | 2021-2023 | |
| Epi Health, LLC | $74.05 | 2022 | |
| Almirall LLC | $63.18 | 2021-2022 | |
| Kyowa Kirin, INC. | $52.43 | 2023-2025 | Poteligeo |
| Mayne Pharma Commercial LLC | $36.96 | 2021-2025 | |
| Fresenius Kabi USA, LLC | $33.37 | 2023 | |
| Biofrontera INC. | $28.80 | 2021 | |
| Janssen Scientific Affairs, LLC | $26.10 | 2024 | Tremfya |
| Journey Medical Corporation | $21.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.54 | 2024 | Cyltezo |
| Dermira, INC. | $15.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.61 | 2024 | Simlandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.